Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322153 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 677
- Enrollment target
NCT00322153: Completed Phase 3 study, sponsored by Forest Laboratories.
NCT00322153 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 677 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00322153, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 677 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).
Primary Outcome
The SIB was developed for the evaluation of cognitive function in patients with more advanced dementia, and evaluates the areas of memory, language, praxis, orientation, and attention. The SIB test items consist of simple, one-step commands presented with gestural cues that are repeated if necessary. The test contains 51 items, and the range of possible scores is 0 to 100 (with 0 being the worst result). The SIB has been shown to be a valid and reliable instrument sensitive to longitudinal chang
Interventions
- DRUG Placebo
- DRUG memantine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 677 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
What the finished NCT00322153 record still lists
NCT00322153 is an interventional study that assigns participants to a tested intervention. The registered 677 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00322153 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00322153 about?
NCT00322153 is a clinical study titled "A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease". The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).
What is the current status of trial NCT00322153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 677 participants. The study started on 2005-06. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00322153?
The interventions under investigation include: Placebo (DRUG), memantine ER (DRUG).
Who is sponsoring clinical trial NCT00322153?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00322153's enrollment target sits among peer trials
677 537th of 2000 higher than 1,464 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05372484 · 678 participants · NA
Rice Technologies for Cervical Cancer Screening and Diagnosis
- NCT06436924 · 678 participants
Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day
- NCT07227337 · 676 participants · NA
Being Safe, Healthy, And Positively Empowered (BSHAPE) Intervention Study
- NCT04788277 · 675 participants
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia